SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In prostate cancer (PCa) patients, the tumor-to-blood ratio (TBR) has been validated as the preferred simplified method for lesional 18F-DCFPyL (a radiolabeled prostate-specific membrane antigen ligand) uptake quantification on PET. In contrast to SUVs, the TBR accounts for variability in arterial input functions caused by differences in total tumor burden between patients (the sink effect). However, TBR depends strongly on tracer uptake interval and has worse repeatability and is less applicable in clinical practice than SUVs. We investigated whether SUV could provide adequate quantification of 18F-DCFPyL uptake on PET/CT in a patient cohort with low PCa burden. Methods: In total, 116 patients with PCa undergoing 18F-DCFPyL PET/CT imaging were retrospectively included. All 18F-DCFPyL-avid lesions suspected of being PCa were semiautomatically delineated. SUVpeak was plotted against TBR for the most intense lesion of each patient. The correlation of SUVpeak and TBR was evaluated using linear regression and was stratified for patients undergoing PET/CT for primary staging, patients undergoing restaging at biochemical recurrence, and patients with metastatic castration-resistant PCa. Moreover, the correlation was evaluated as a function of tracer uptake time, prostate-specific antigen level, and PET-positive tumor volume. Results: In total, 436 lesions were delineated (median, 1 per patient; range, 1-66). SUVpeak correlated well with TBR in patients with PCa and a total tumor volume of less than 200 cm3 (R2 = 0.931). The correlation between SUV and TBR was not affected by disease setting, prostate-specific antigen level, or tumor volume. SUVpeak depended less on tracer uptake time than did TBR. Conclusion: For 18F-DCFPyL PET/CT, SUVpeak correlates strongly with TBR. Therefore, it is a valuable simplified, semiquantitative measurement in patients with low-volume PCa (<200 cm3). SUVpeak can therefore be applied in 18F-DCFPyL PET assessment as an imaging biomarker to characterize tumors and to monitor treatment outcomes.

Original languageEnglish
Pages (from-to)1264-1269
Number of pages6
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume62
Issue number9
Early online date28 Jan 2021
DOIs
Publication statusPublished - 1 Sep 2021

Cite this